148 related articles for article (PubMed ID: 38011421)
1. Evaluation of safety of rituximab in patients with multiple sclerosis: A retrograde study.
Majdinasab N; Sadrian M; Kashipazha D; Moradi M
Curr J Neurol; 2020 Jul; 19(3):103-106. PubMed ID: 38011421
[No Abstract] [Full Text] [Related]
2. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
3. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
[No Abstract] [Full Text] [Related]
4. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study.
Zhao D; Zhao C; Lu J; Han Y; Sun T; Ren K; Ma C; Zhang C; Li H; Guo J
Mult Scler Relat Disord; 2023 Feb; 70():104518. PubMed ID: 36657326
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the efficacy and safety of Zytux
Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
11. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Juto A; Fink K; Al Nimer F; Piehl F
Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C; Bovis F; Novi G; Capobianco M; Lanzillo R; Frau J; Repice AM; Hakiki B; Realmuto S; Bonavita S; Curti E; Brambilla L; Mataluni G; Cavalla P; Di Sapio A; Signoriello E; Barone S; Maniscalco GT; Maietta I; Maraffi I; Boffa G; Malucchi S; Nozzolillo A; Coghe G; Mechi C; Salemi G; Gallo A; Sacco R; Cellerino M; Malentacchi M; De Angelis M; Lorefice L; Magnani E; Prestipino E; Sperli F; Brescia Morra V; Fenu G; Barilaro A; Abbadessa G; Signori A; Granella F; Amato MP; Uccelli A; Gobbi C; Sormani MP
Mult Scler; 2020 Oct; 26(12):1519-1531. PubMed ID: 31573386
[TBL] [Abstract][Full Text] [Related]
13. Impact of multiple sclerosis phenotypes on burden of disease in Finland.
Purmonen T; Hakkarainen T; Tervomaa M; Ruutiainen J
J Med Econ; 2020 Feb; 23(2):156-165. PubMed ID: 31617776
[No Abstract] [Full Text] [Related]
14. Impact of rituximab in Mexican patients with Multiple Sclerosis-A single-center retrospective study.
Bribiesca-Contreras E; García-Estrada C; Gómez-Figueroa E; Zertuche-Ortuño L; Rodríguez-Rivas R; Marcín-Sierra M; Delgado-Niño M; Rivas-Alonso V; Corona-Vázquez T; Flores-Rivera J
Mult Scler Relat Disord; 2022 Feb; 58():103485. PubMed ID: 35042092
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Rituximab: Experience of a Single Multiple Sclerosis Center.
Alldredge B; Jordan A; Imitola J; Racke MK
Clin Neuropharmacol; 2018; 41(2):56-59. PubMed ID: 29389745
[TBL] [Abstract][Full Text] [Related]
16. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.
Scotti B; Disanto G; Sacco R; Guigli M; Zecca C; Gobbi C
PLoS One; 2018; 13(5):e0197415. PubMed ID: 29758075
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
19. Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascón-Giménez F; Alcalá C; Ramió-Torrentà L; Montero P; Matías-Guiu J; Gómez-Estevez I; Oreja-Guevara C; Gil-Perotín S; Blanco Y; Carcelén M; Quintanilla-Bordás C; Costa L; Villar LM; Martínez-Rodriguez JE; Domínguez JA; Calles C; González I; Sotoca J; Oterino A; Lucas-Jimenez C; Pérez-Miralles F; Casanova B
Front Neurol; 2023; 14():1060696. PubMed ID: 36959824
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
